Silence Therapeutics plc (SLN)
NASDAQ: SLN · IEX Real-Time Price · USD
21.25
+0.59 (2.86%)
Apr 16, 2024, 4:00 PM EDT - Market closed

Silence Therapeutics Income Statement

Millions GBP. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
25.3817.512.425.480.240
Revenue Growth (YoY)
44.99%40.97%126.59%2145.49%--
Cost of Revenue
10.3210.887.463.7600
Gross Profit
15.066.624.961.720.240
Selling, General & Admin
20.6419.6120.0113.989.6410.83
Research & Development
44.0335.6130.7720.2113.349.74
Other Operating Expenses
0003.370-0.01
Operating Expenses
64.6655.2150.7737.5622.9820.57
Operating Income
-49.6-48.59-45.81-35.85-22.73-20.57
Interest Expense / Income
2.150.050.050.320.160
Other Expense / Income
-1.45-1.27-0.01-0.13-0.03-0.04
Pretax Income
-50.31-47.37-45.86-36.04-22.87-20.53
Income Tax
-7.04-6.88-6.45-3.49-3.29-2.12
Net Income
-43.27-40.49-39.41-32.55-19.58-18.41
Shares Outstanding (Basic)
116108907878-
Shares Change
7.74%19.94%14.55%---
EPS (Basic)
-----0.78-0.78
EPS (Diluted)
-----0.78-0.78
Free Cash Flow
-39.4-45.65.5-11.281.72-16.89
Free Cash Flow Per Share
-1.02-1.270.18-0.430.07-
Gross Margin
59.34%37.83%39.94%31.34%100.00%-
Operating Margin
-195.48%-277.66%-369.02%-654.26%-9317.21%-
Profit Margin
-170.51%-231.35%-317.44%-594.03%-8025.41%-
Free Cash Flow Margin
-155.25%-260.53%44.26%-205.95%704.10%-
EBITDA
-47.7-46.84-45.39-35.24-22.26-20.15
EBITDA Margin
-187.96%-267.66%-365.63%-643.22%-9120.90%-
Depreciation & Amortization
0.460.480.410.480.450.38
EBIT
-48.16-47.32-45.8-35.72-22.71-20.53
EBIT Margin
-189.79%-270.39%-368.94%-651.91%-9306.15%-
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).